{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T09:21:03Z","timestamp":1774689663270,"version":"3.50.1"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Pediatric pustular psoriasis (PPP) is an autoimmune skin disease that seriously affects the physical and mental health of children. The IL-36RN (Interleukin-36 Receptor Antagonist) gene plays a key role in the pathogenesis of PPP. This review comprehensively elaborates on the research progress of IL-36RN in the context of the pathogenesis and treatment of PPP, covering the basic structure, function, mutation sites and types, and inheritance patterns of the gene and its role in the pathogenesis of PPP. In addition, we discussed the frequency of IL-36RN mutations in patients with different types of PPP and the treatment methods for these patients, aiming to provide a valuable reference for further research and treatment of this disease.<\/jats:p>","DOI":"10.3389\/fped.2025.1520804","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T17:25:08Z","timestamp":1742405108000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["IL-36RN gene: key insights into its role in pediatric pustular psoriasis pathogenesis and treatment"],"prefix":"10.3389","volume":"13","author":[{"given":"Ye","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changcheng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xurui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1365-4632.2004.02182.x","article-title":"Epidemiology of childhood psoriasis: a study of 419 patients from northern India","volume":"43","author":"Kumar","year":"2004","journal-title":"Int J Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/archderm.1991.01680080075005","article-title":"Generalized pustular psoriasis. A review of 63 cases","volume":"127","author":"Zelickson","year":"1991","journal-title":"Arch Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40272-020-00383-6","article-title":"Pharmacological management of pediatric pustular psoriasis","volume":"22","author":"Huang","year":"2020","journal-title":"Paediatr Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1377381","DOI":"10.3389\/fmed.2024.1377381","article-title":"Clinical efficacy and safety of secukinumab in the treatment of generalized pustular psoriasis in the pediatric population: a systematic review of the literature","volume":"11","author":"Wei","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jaad.2022.04.064","article-title":"Real-world data on the clinical use of secukinumab in pediatric generalized pustular psoriasis: a 48-week retrospective study","volume":"88","author":"Ruan","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"42594","DOI":"10.1074\/jbc.M111.267922","article-title":"Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36\u03b1, IL-36\u03b2, and IL-36\u03b3) or antagonist (IL-36Ra) activity","volume":"286","author":"Towne","year":"2011","journal-title":"J Biol Chem"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0318","DOI":"10.1590\/0037-8682-0318-2021","article-title":"Pediatric COVID-19 patient with exacerbated generalized pustular psoriasis","volume":"54","author":"Pala","year":"2021","journal-title":"Rev Soc Bras Med Trop"},{"key":"B9","first-page":"17","article-title":"Collodion baby: the out-come of long-term follow-up","volume":"76","author":"Pongprasit","year":"1993","journal-title":"J Med Assoc Thai"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/exd.13387","article-title":"Mutation in IL36RN impairs the processing and regulatory function of the interleukin-36-receptor antagonist and is associated with DITRA syndrome","volume":"28","author":"Bal","year":"2019","journal-title":"Exp Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.jid.2019.11.024","article-title":"Rare loss-of-function mutation in SERPINA3 in generalized pustular psoriasis","volume":"140","author":"Frey","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.3389\/fimmu.2018.02239","article-title":"Clinical and genetic heterogeneity of CARD14 mutations in psoriatic skin disease","volume":"9","author":"Israel","year":"2018","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ajhg.2014.04.005","article-title":"AP1S3 mutations are associated with pustular psoriasis and impaired toll-like receptor 3 trafficking","volume":"94","author":"Setta-Kaffetzi","year":"2014","journal-title":"Am J Hum Genet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1038\/jid.2013.267","article-title":"Prevalent and rare mutations in IL-36RN gene in Chinese patients with generalized pustular psoriasis and psoriasis vulgaris","volume":"133","author":"Li","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.dci.2012.04.014","article-title":"Identification, cloning and characterisation of interleukin-1F5 (IL-36RN) in the chicken","volume":"38","author":"Gibson","year":"2012","journal-title":"Dev Comp Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cytogfr.2020.06.006","article-title":"IL-36 in chronic inflammation and cancer","volume":"55","author":"Neurath","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/5584_2020_488","article-title":"Interleukin-36: structure, signaling and function","volume":"21","author":"Zhou","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-94-024-0921-5_2","article-title":"The interleukin-1 family","volume":"941","author":"Yazdi","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00535-022-01936-x","article-title":"Pro- and anti-inflammatory roles of interleukin (IL)-33, IL-36, and IL-38 in inflammatory bowel disease","volume":"58","author":"Andoh","year":"2023","journal-title":"J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1684\/ecn.2011.0288","article-title":"IL-37: a new anti-inflammatory cytokine of the IL-1 family","volume":"22","author":"Boraschi","year":"2011","journal-title":"Eur Cytokine Netw"},{"key":"B22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cyto.2015.06.017","article-title":"The interleukin (IL)-1 cytokine family\u2013balance between agonists and antagonists in inflammatory diseases","volume":"76","author":"Palomo","year":"2015","journal-title":"Cytokine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.4049\/jimmunol.167.3.1440","article-title":"Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2","volume":"167","author":"Debets","year":"2001","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1073\/pnas.1121534109","article-title":"IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist","volume":"109","author":"Van","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3390\/ijms20071649","article-title":"IL-36 Cytokines: regulators of inflammatory responses and their emerging role in immunology of reproduction","volume":"20","author":"MurrietaMurrieta-Coxca","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/jid.2012.490","article-title":"Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes","volume":"133","author":"Setta-Kaffetzi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00403-015-1611-x","article-title":"Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients","volume":"308","author":"Wang","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1038\/jid.2014.177","article-title":"IL36RN mutations underlie impetigo herpetiformis","volume":"134","author":"Sugiura","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/humu.22203","article-title":"Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis","volume":"34","author":"Farooq","year":"2013","journal-title":"Hum Mutat"},{"key":"B30","doi-asserted-by":"publisher","first-page":"108930","DOI":"10.1016\/j.clim.2022.108930","article-title":"Digenic inheritance of IL-36RA and SEC61A1 mutations underlies generalized pustular psoriasis with hypogammaglobulinemia","volume":"235","author":"Almutairi","year":"2022","journal-title":"Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis","volume":"89","author":"Onoufriadis","year":"2011","journal-title":"Am J Hum Genet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2174\/18735592MTEx9NTk2y","article-title":"Colorectal cancer epidemiology: recent trends and impact on outcomes","volume":"22","author":"Baidoun","year":"2021","journal-title":"Curr Drug Targets"},{"key":"B33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41423-020-0519-3","article-title":"\u201cAutoinflammatory psoriasis\u201d\u2014genetics and biology of pustular psoriasis","volume":"18","author":"Uppala","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36\u2013receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jid.2016.04.038","article-title":"IL36RN mutations affect protein expression and function: a basis for genotype-phenotype correlation in pustular diseases","volume":"136","author":"Tauber","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.3389\/fimmu.2019.02532","article-title":"Biology of IL-36 signaling and its role in systemic inflammatory diseases","volume":"10","author":"Yuan","year":"2019","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"155897","DOI":"10.1016\/j.cyto.2022.155897","article-title":"Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions","volume":"156","author":"Sachen","year":"2022","journal-title":"Cytokine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","article-title":"Clinical and genetic differences between pustular psoriasis subtypes","volume":"143","author":"Twelves","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jdermsci.2017.03.004","article-title":"Topical application of glycolic acid suppresses the UVB induced IL-6, IL-8, MCP-1 and COX-2 inflammation by modulating NF-\u03baB signaling pathway in keratinocytes and mice skin","volume":"86","author":"Tang","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/jdv.19492","article-title":"Serine deficiency exacerbates psoriatic skin inflammation by regulating S-adenosyl methionine-dependent DNA methylation and NF-\u03baB signalling activation in keratinocytes","volume":"38","author":"Meng","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00011-013-0633-0","article-title":"TNF-\u03b1 signalling and inflammation: interactions between old acquaintances","volume":"62","author":"Zelov\u00e1","year":"2013","journal-title":"Inflamm Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1152\/physrev.2001.81.2.807","article-title":"Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation","volume":"81","author":"Kyriakis","year":"2001","journal-title":"Physiol Rev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4161\/cc.9.3.10541","article-title":"P38delta mitogen-activated protein kinase regulates skin homeostasis and tumorigenesis","volume":"9","author":"Efimova","year":"2010","journal-title":"Cell Cycle"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.jid.2017.10.037","article-title":"The p38 mitogen-activated protein kinase critically regulates human keratinocyte inflammasome activation","volume":"138","author":"Fenini","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3390\/life11070623","article-title":"Characteristics of pruritus in various clinical variants of psoriasis: results of the multinational, multicenter, cross-sectional study","volume":"11","author":"Jaworecka","year":"2021","journal-title":"Life (Basel)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2s","DOI":"10.1177\/1203475417733414","article-title":"Acitretin use in dermatology","volume":"21","author":"Guenther","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/ar.24921","article-title":"Retinoid receptors are expressed in mouse and human lungs","volume":"305","author":"Channabasappa","year":"2022","journal-title":"Anat Rec (Hoboken)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00403-008-0872-z","article-title":"Effects of acitretin on proliferative inhibition and RANTES production of HaCaT cells","volume":"300","author":"Zhang","year":"2008","journal-title":"Arch Dermatol Res"},{"key":"B49","first-page":"6","article-title":"Extemporaneous compounding of oral acitretin suspension for pediatric patient with generalized pustular psoriasis","volume":"20","author":"Choo","year":"2016","journal-title":"Int J Pharm Compd"},{"key":"B50","doi-asserted-by":"publisher","first-page":"8199","DOI":"10.2147\/JIR.S485077","article-title":"Successful treatment of pediatric generalized pustular psoriasis (GPP) with spesolimab: 5 case reports and evaluations of circulating IL-36 levels","volume":"17","author":"Chen","year":"2024","journal-title":"J Inflamm Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3109\/09546634.2015.1115813","article-title":"Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis","volume":"27","author":"Bulbul Baskan","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/bjd.14326","article-title":"Systemic treatments in childhood psoriasis: a French multicentre study on 154 children","volume":"174","author":"Charbit","year":"2016","journal-title":"Br J Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40257-021-00658-9","article-title":"Treatment options and goals for patients with generalized pustular psoriasis","volume":"23","author":"Krueger","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.2147\/OPTH.S279051","article-title":"A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments","volume":"14","author":"Periman","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"Cd011535","DOI":"10.1002\/14651858","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.annder.2019.03.006","article-title":"Psoriasis: initial assessment and practical therapy evaluation","volume":"146","author":"Richard","year":"2019","journal-title":"Ann Dermatol Venereol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1111\/jdv.15579","article-title":"Biological treatments for paediatric psoriasis: a retrospective observational study on biological drug survival in daily practice in childhood psoriasis","volume":"33","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2015.09.056","article-title":"Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis","volume":"74","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1159\/000096202","article-title":"Anti-TNF-alpha therapy in childhood pustular psoriasis","volume":"213","author":"Pereira","year":"2006","journal-title":"Dermatology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/dth.12065","article-title":"Juvenile generalized pustular psoriasis treated with etanercept","volume":"27","author":"Fialov\u00e1","year":"2014","journal-title":"Dermatol Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1525-1470.2006.00174.x","article-title":"Etanercept for psoriasis in the pediatric population: experience in nine patients","volume":"23","author":"Hawrot","year":"2006","journal-title":"Pediatr Dermatol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1684\/ejd.2011.1432","article-title":"Etanercept, childhood and long-term safety: a case of five years treatment","volume":"21","author":"Mazzotta","year":"2011","journal-title":"Eur J Dermatol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/jdv.17002","article-title":"Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomized, controlled trial","volume":"35","author":"Bodemer","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1002\/ski2.343","article-title":"Targeted review of IL36RN mutations in patients with generalised pustular psoriasis","volume":"4","author":"Krueger","year":"2024","journal-title":"Skin Health Dis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s13555-021-00666-x","article-title":"Ixekizumab 80mg every 2 weeks treatment beyond week 12 for Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis","volume":"12","author":"Morita","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e15382","DOI":"10.1111\/dth.15382","article-title":"Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient","volume":"35","author":"Megna","year":"2022","journal-title":"Dermatol Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e15878","DOI":"10.1111\/dth.15878","article-title":"Generalized pustular psoriasis recurring during pregnancy and lactation successfully treated with ixekizumab","volume":"35","author":"Huang","year":"2022","journal-title":"Dermatol Ther"},{"key":"B70","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1007\/s13555-023-01037-4","article-title":"Efficacy and safety of spesolimab in patients with generalized pustular psoriasis: a subgroup analysis of Chinese patients in the effisayil 1 trial","volume":"13","author":"Tsai","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(23)01378-8","article-title":"Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (effisayil 2): an international, multicentre, randomised, placebo-controlled trial","volume":"402","author":"Morita","year":"2023","journal-title":"Lancet"},{"key":"B72","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/10600280241252688","article-title":"Spesolimab: a review of the first IL-36 blocker approved for generalized pustular psoriasis","volume":"59","author":"Pathak","year":"2025","journal-title":"Ann Pharmacother"},{"key":"B73","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/1346-8138.17074","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, phase 3 trial","volume":"51","author":"Imafuku","year":"2024","journal-title":"J Dermatol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1520804\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T17:25:13Z","timestamp":1742405113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1520804\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":73,"alternative-id":["10.3389\/fped.2025.1520804"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1520804","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"article-number":"1520804"}}